This page was retrieved from https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions at Thu Nov 19 09:50:33 2026 when TheGovernmentSays.com first noticed it existed

Government backs modernisation of gene therapy definitions - GOV.UK Skip to main content
Press release

Government backs modernisation of gene therapy definitions

Proposed changes will provide clearer regulatory pathway for certain synthetic gene therapies, supporting life sciences innovation while maintaining safety.

Close up of a microscope.

The government today (19 November 2026) confirmed plans to modernise the legal definition of gene therapy medicinal products (GTMPs), enabling certain synthetic gene therapies and novel genome-editing treatments to be regulated under the UK’s established advanced therapies framework. 

The proposals, published in the government’s response to a consultation led by the Medicines and Healthcare products Regulatory Agency (MHRA) and Department of Health in Northern Ireland, received support from 83% of respondents. Subject to international notification procedures and parliamentary approval, they will amend the Human Medicines Regulations 2012 to reflect advances in synthetic genetic material and genome-editing technologies. 

The changes will give developers greater certainty about how these medicines are classified and the regulatory requirements they must meet, helping them plan with confidence, while supporting innovation in the UK life sciences sector. The existing approval process and standards for safety, quality and efficacy will remain unchanged, and medicines already licensed will not need to be reclassified, avoiding unnecessary disruption for developers. 

The announcement was made at the inaugural DIA-MHRA Global Summit, held in London on 16–17 November 2026 as part of London Life Sciences Week. Hosted jointly by the MHRA and the Drug Information Association (DIA), the Summit brings together international regulators, industry leaders, researchers, healthcare professionals and patient representatives to explore how global collaboration can support innovation and how this innovation can reach patients faster. 

MHRA Executive Director Operations, Julian Beach, said: 

“Scientific advances are opening up new possibilities for innovative gene therapies, and it is important that regulation keeps pace. 

“These proposals will address a gap in the current definition, providing a clearer route to licensing for certain synthetic gene therapies and greater certainty for developers about the regulatory requirements they need to meet. 

“By providing greater certainty for developers, we can help attract investment, strengthen the UK’s position as a leader in life sciences and support the development of potentially life-saving new treatments for patients.” 

Advances in gene therapies have increasingly challenged the suitability of the current UK definitions of a class of medicines called Advanced Therapy Medicinal Products (ATMPs). These definitions, originally developed in 2007, were created at a time when treatments were based on a smaller range of technologies. Today, innovative therapies can involve synthetic genetic material, new forms of genome editing and highly engineered cells and tissues. Many of these products may not fit neatly into the categories of ATMPs set out in the Human Medicines Regulations 2012. 

The MHRA, acting jointly with the Department of Health in Northern Ireland (DoH), conducted a six-week public consultation on the proposals to update the definition of GTMPs. The consultation sought views on a series of targeted amendments intended to modernise the framework, accommodate emerging technologies and ensure the UK regulatory system remains fit for purpose as the field of genetic medicine continues to evolve, through global alignment.  

Responses were received from a broad range of stakeholders, including pharmaceutical and biotechnology companies, academic institutions, NHS organisations, patient groups and professional bodies with respondents broadly supportive of the proposals. 

Following the consultation, the MHRA will now progress the required legislation to revise the definitions to take a more technologically neutral approach. Once implemented, Gene Therapy Medicinal Product (GTMP) classification will depend on whether the active substance contains a recombinant or synthetic nucleic acid that undergoes transcription or translation, or whether the mechanism of action involves sequence specific genome editing. This approach maintains continuity with existing ATMP principles while ensuring that modern synthetic platforms, and gene editing systems are appropriately captured within the framework. 

Notes to Editors 

  • The Government response: Consultation on the regulation of gene therapy medicinal products can be viewed here  

  • The MHRA launched the UK-wide consultation on 11 May 2026, seeking views on proposals to modernise the legal definition of gene therapy medicinal products (GTMPs). The consultation closed on 22 June 2026. The original MHRA press release, MHRA opens UK-wide consultation on redefining gene therapies, provides further background. 

  • The DIA-MHRA Global Summit, where this announcement was made, is part of London Life Sciences Week, a concentrated demonstration of the UK’s life sciences offer, and MHRA is proud to have a key role in connecting science, regulation, investment and patient benefit. Across key areas of focus this week – including women’s health, clinical research, AI, manufacturing, advanced therapeutics, and rare disease – better regulation means better evidence, clearer routes for innovators and greater potential for patient benefit. 

  • The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. The MHRA is an executive agency of the Department of Health and Social Care. 

  • For media enquiries, please contact newscentre@mhra.gov.uk or call 020 3080 7651.